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Studies in yeast, flies and worms have indicated that 
overexpression of the protein deacetylase Sir2 increases 
longevity [1]. Mammals possess 7 paralogs of the Sir2 
gene, being Sirt1 the most similar one closest to Sir2 
[1]. In our recent work [2], we have used a genetic 
approach to address the effect of Sirt1 on mammalian 
ageing. In particular, we have generated two 
independent lines of transgenic mice that globally 
overexpress Sirt1 (≈3-fold) under the control of its own 
regulatory elements (Sirt1-tg mice). Previously, we had 
shown that these Sirt1-tg mice are protected from the 
metabolic damage associated to high-fat diet (HFD) 
through the inhibition of NFκB inflammatory pathway 
and the activation of PGC1α antioxidant response [3]. 
The potent beneficial effects of Sirt1 in protecting from 
metabolic syndrome and its associated pathologies, such 
as diabetes and fatty liver, have consistently emerged in 
a variety of mouse models as one of the main 
physiological activities of Sirt1 [3-7]. We now report 
the ageing and longevity of Sirt1-tg mice [2]. 
 
We have observed that old Sirt1-tg mice show a better 
health during aging compared to their wild-type 
littermates. In particular, old Sirt1-tg mice are partially 
protected from diabetes, osteoporosis and cancer. 
However, these beneficial effects on health are not 
potent enough to increase lifespan and the survival 
curves of Sirt-tg and wild-type mice are 
indistinguishable. Failure to extend longevity may 
simply reflect the fact that Sirt1 overexpression in Sirt1-
tg mice is not sufficiently high, or it may indicate that 
Sirt1 does not protect from all aging-associated 
pathologies. In this regard, Sirt1-tg mice showed a 
significant decrease in  the incidence of carcinomas  and  
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sarcomas, but their incidence of lymphomas was 
comparable to wild-type mice. Of note, lymphomas are 
the most abundant cancer type in the strain of mice used 
and are a probable cause of death [8]; while, in general, 
carcinomas and sarcomas in old mice are at an incipient 
stage and mice presumably die of other aging-
associated pathologies. Similarly, it is conceivable that 
other pathologies not studied in our work, such as 
cardiovascular or renal failure, could be insensitive to 
Sirt1 or may require higher levels of Sirt1 to be 
ameliorated. Finally, other Sir2 paralogs present in the 
mammalian genome may also contribute with important 
anti-aging functions and together recapitulate the 
longevity effect of Sir2 in other model organisms.  
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Figure1. Sirt1 protects from damage and improves 
healthspan.  
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employment of a new model of diet-promoted liver 
cancer and the demonstration that Sirt1 is a potent 
protector of this type of liver carcinogenesis. In 
particular, we performed a protocol based on the 
injection of the hepatocarcinogen ditehylnitrosamine 
(DEN) followed by high-fat diet (HFD) feeding. 
Independently, other investigators have recently 
demonstrated that HFD promotes liver cancer through 
the induction of systemic inflammation [9]. In the case 
of Sirt1, we show that it protects dramatically from this 
type of carcinogenesis not only by diminishing the 
inflammatory response associated to HFD, but also by 
protecting from the initial acute DNA damage triggered 
by DEN [2]. The latter observation is in concordance 
with previous in vitro reports that demonstrated a role 
for Sirt1 in DNA repair [10,11]. Together, and despite 
the lack of effect on longevity, our results demonstrate a 
beneficial role for Sirt1 in liver damage, metabolic 
syndrome-associated liver cancer, and in a variety of 
aging-associated pathologies, such as spontaneous 
carcinomas and sarcomas, diabetes and osteoporosis [2] 
(Figure 1). 
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